Jazz Pharmaceuticals
Identifying, developing and commercializing meaningful products that address unmet medical needs.
Launch date
Employees
Market cap
€6.0b
Enterprise valuation
€9.4b (Public information from Sep 2024)
Share price
$109.57 JAZZ
Dublin County Dublin (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.4b | 3.1b | 3.7b | 3.8b | 4.0b | 4.3b | 4.5b |
| % growth | 9 % | 31 % | 18 % | 5 % | 5 % | 7 % | 5 % |
| EBITDA | 1.0b | 696m | 1.1b | 1.2b | 1.8b | 1.9b | 2.0b |
| % EBITDA margin | 43 % | 22 % | 30 % | 32 % | 44 % | 43 % | 45 % |
| Profit | 239m | (330m) | (224m) | 415m | 498m | 614m | 698m |
| % profit margin | 10 % | (11 %) | (6 %) | 11 % | 12 % | 14 % | 15 % |
| EV / revenue | 4.3x | 4.3x | 4.1x | 3.1x | 2.7x | 2.2x | 1.7x |
| EV / EBITDA | 10.0x | 19.1x | 13.4x | 9.6x | 6.0x | 5.1x | 3.9x |
| R&D budget | 335m | 506m | 590m | 850m | - | - | - |
| R&D % of revenue | 14 % | 16 % | 16 % | 22 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $7.1m | Series A | |
$250m | Series B | ||
| N/A | $108m | IPO | |
$7.0m | Post IPO Equity | ||
| N/A | $120m | Post IPO Debt | |
* | N/A | $850m | Post IPO Debt |
| Total Funding | €234m | ||
Recent News about Jazz Pharmaceuticals
EditInvestments by Jazz Pharmaceuticals
Edit
ACQUISITION by Jazz Pharmaceuticals Feb 2021
ACQUISITION by Jazz Pharmaceuticals Dec 2013
ACQUISITION by Jazz Pharmaceuticals Apr 2012
ACQUISITION by Jazz Pharmaceuticals May 2016
ACQUISITION by Jazz Pharmaceuticals Jul 2019
ACQUISITION by Jazz Pharmaceuticals Aug 2019
